204 related articles for article (PubMed ID: 26018348)
21. Switch from calcineurin inhibitors to sirolimus-induced renal recovery in heart transplant recipients in the midterm follow-up.
Bestetti R; Theodoropoulos TA; Burdmann EA; Filho MA; Cordeiro JA; Villafanha D
Transplantation; 2006 Mar; 81(5):692-6. PubMed ID: 16534470
[TBL] [Abstract][Full Text] [Related]
22. Calcineurin inhibitor- and corticosteroid-free immunosuppression in pediatric heart transplant patients.
Sierra CM; Tan R; Eguchi J; Bailey L; Chinnock RE
Pediatr Transplant; 2017 Feb; 21(1):. PubMed ID: 27658616
[TBL] [Abstract][Full Text] [Related]
23. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
Watson CJ; Gimson AE; Alexander GJ; Allison ME; Gibbs P; Smith JC; Palmer CR; Bradley JA
Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
[TBL] [Abstract][Full Text] [Related]
24. New approaches to de novo immunosuppression and steroid elimination.
Lebranchu Y
Transplant Proc; 2009; 41(6 Suppl):S39-41. PubMed ID: 19651295
[TBL] [Abstract][Full Text] [Related]
25. Empiric switch from calcineurin inhibitor to sirolimus-based immunosuppression in pediatric heart transplantation recipients.
Loar RW; Driscoll DJ; Kushwaha SS; Cramer CH; O'Leary PW; Daly RC; Mauriello DA; Johnson JN
Pediatr Transplant; 2013 Dec; 17(8):794-9. PubMed ID: 24164828
[TBL] [Abstract][Full Text] [Related]
26. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.
Kushwaha SS; Khalpey Z; Frantz RP; Rodeheffer RJ; Clavell AL; Daly RC; McGregor CG; Edwards BS
J Heart Lung Transplant; 2005 Dec; 24(12):2129-36. PubMed ID: 16364861
[TBL] [Abstract][Full Text] [Related]
27. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
[TBL] [Abstract][Full Text] [Related]
28. Renal function in renal or liver transplant recipients after conversion from a calcineurin inhibitor to sirolimus.
Bäckman L; Reisaeter AV; Wramner L; Ericzon BG; Salmela K; Brattström C
Clin Transplant; 2006; 20(3):336-9. PubMed ID: 16824151
[TBL] [Abstract][Full Text] [Related]
29. Improvement of renal graft function after conversion from a calcineurin inhibitor including immunosuppression to a mycophenolate sodium including regimen: a 4-year follow-up.
Heeg MH; Mueller GA; Bramlage C; Homayounfar K; Muehlhausen J; Leha A; Koziolek MJ
Transplant Proc; 2013; 45(1):142-7. PubMed ID: 23375288
[TBL] [Abstract][Full Text] [Related]
30. Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients--a three-yr serial echocardiographic substudy of the randomized controlled CENTRAL trial.
Murbraech K; Massey R; Undset LH; Midtvedt K; Holdaas H; Aakhus S
Clin Transplant; 2015 Aug; 29(8):678-84. PubMed ID: 25982053
[TBL] [Abstract][Full Text] [Related]
31. Everolimus with early withdrawal or reduced-dose calcineurin inhibitors improves renal function in liver transplant recipients: A systematic review and meta-analysis.
Lin M; Mittal S; Sahebjam F; Rana A; Sood GK
Clin Transplant; 2017 Feb; 31(2):. PubMed ID: 27862340
[TBL] [Abstract][Full Text] [Related]
32. Experience with belatacept rescue therapy in kidney transplant recipients.
Brakemeier S; Kannenkeril D; Dürr M; Braun T; Bachmann F; Schmidt D; Wiesener M; Budde K
Transpl Int; 2016 Nov; 29(11):1184-1195. PubMed ID: 27514317
[TBL] [Abstract][Full Text] [Related]
33. Alemtuzumab and minimization immunotherapy in kidney transplantation: long-term results of comparison with rabbit anti-thymocyte globulin and standard triple maintenance therapy.
Zachariah M; Nader ND; Brar J; Singh N; Venuto R; Patel S; Said M; Laftavi MR; Pankewycz O
Transplant Proc; 2014; 46(1):94-100. PubMed ID: 24507032
[TBL] [Abstract][Full Text] [Related]
34. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
[TBL] [Abstract][Full Text] [Related]
35. Anti-CD25 monoclonal antibody replacement therapy for chronic kidney disease in liver transplant recipients.
Walsh C; Barkun J; Tchervenkov J; Deschenes M; Ghali P; Wong P; Chaudhury P; Paraskevas S; Metrakos P; Cantarovich M
Transplantation; 2013 Feb; 95(3):495-500. PubMed ID: 23296149
[TBL] [Abstract][Full Text] [Related]
36. The Effect of Mammalian Target of Rapamycin Versus Calcineurin Inhibitor-based Immunosuppression on Measured Versus Estimated Glomerular Filtration Rate After Orthotopic Liver Transplantation.
Zitta S; Schaffellner S; Gutschi J; Meinitzer A; Kniepeiss D; Artinger K; Reibnegger G; Rosenkranz AR; Wagner D
Transplantation; 2015 Jun; 99(6):1250-6. PubMed ID: 25606796
[TBL] [Abstract][Full Text] [Related]
37. Evolution of Renal Function in Renal Allograft Recipients Under Various Everolimus-Based Immunosuppressive Regimens.
Skalioti C; Marinaki S; Darema M; Lionaki S; Antonakopoulos N; Zavos G; Boletis J
Transplant Proc; 2015; 47(6):1705-10. PubMed ID: 26293038
[TBL] [Abstract][Full Text] [Related]
38. Basiliximab with delayed introduction of calcineurin inhibitors as a renal-sparing protocol following liver transplantation in children with renal impairment.
Mouzaki M; Yap J; Avinashi V; Babu A; Fu A; Deangelis M; Van Roestel K; Ghanekar A; Kamath B; Avitzur Y; Fecteau A; Jones N; Ling S; Grant D; Ng V
Pediatr Transplant; 2013 Dec; 17(8):751-6. PubMed ID: 24118898
[TBL] [Abstract][Full Text] [Related]
39. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
Cataneo-Dávila A; Zúñiga-Varga J; Correa-Rotter R; Alberú J
Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355
[TBL] [Abstract][Full Text] [Related]
40. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
